212 related articles for article (PubMed ID: 18093408)
1. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Brooks DP; Ruffolo RR
J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
[TBL] [Abstract][Full Text] [Related]
3. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
Nap A; Belterman CN; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):220-7. PubMed ID: 14689369
[TBL] [Abstract][Full Text] [Related]
4. The clinical profile of the angiotensin II receptor blocker eprosartan.
Hedner T
J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
[TBL] [Abstract][Full Text] [Related]
5. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
Blankestijn PJ; Rupp H
Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
[TBL] [Abstract][Full Text] [Related]
6. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
[TBL] [Abstract][Full Text] [Related]
7. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
Rayner B; Jaeger B; Verboom CN; Pascoe M
Cardiovasc J S Afr; 2004; 15(1):32-7. PubMed ID: 14997235
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
[TBL] [Abstract][Full Text] [Related]
9. [Prospects for pharmacological effects on renin-angiotensin and sympathetic nervous systems in patients with arterial hypertension].
Chikhladze NM
Ter Arkh; 2000; 72(12):67-9. PubMed ID: 11201840
[No Abstract] [Full Text] [Related]
10. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
11. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
12. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
13. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Neumann J; Ligtenberg G; Oey L; Koomans HA; Blankestijn PJ
J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
Brooks DP; Ohlstein EH; Ruffolo RR
Am Heart J; 1999 Sep; 138(3 Pt 2):246-51. PubMed ID: 10467220
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
Garg JP; Ellis R; Elliott WJ; Hasabou N; Chua D; Chertow GM; Bakris GL
Am J Nephrol; 2005; 25(4):393-9. PubMed ID: 16088080
[TBL] [Abstract][Full Text] [Related]
16. Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
Cardiovasc J S Afr; 2004; 15(2):91-2. PubMed ID: 15148545
[No Abstract] [Full Text] [Related]
17. Re: Heusser et al: elevation of sympathetic activity by eprosartan in young male subjects.
Rupp H
Am J Hypertens; 2004 Mar; 17(3):281; author reply 281-3. PubMed ID: 15001205
[No Abstract] [Full Text] [Related]
18. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
19. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
Hedner T
J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
[TBL] [Abstract][Full Text] [Related]
20. Elevation of sympathetic activity by eprosartan in young male subjects.
Heusser K; Vitkovsky J; Raasch W; Schmieder RE; Schobel HP
Am J Hypertens; 2003 Aug; 16(8):658-64. PubMed ID: 12878372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
